Get the Stockscreener App
0.6956
0.81%
0.0056
Xilio Therapeutics Inc stock is traded at $0.6956, with a volume of 113.93K.
It is up +0.81% in the last 24 hours and down -30.79% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.69
Open:
$0.69
24h Volume:
113.93K
Relative Volume:
0.24
Market Cap:
$31.55M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.235
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-1.33%
1M Performance:
-30.79%
6M Performance:
-19.26%
1Y Performance:
+6.04%
1-Day Range:
$0.654
$0.7199
1-Week Range:
$0.63
$0.7199
52-Week Range:
$0.5001
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.6956 | 31.55M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.10 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.79 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.27 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.82 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 44.5% in January - Defense World
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Increase in Short Interest - Defense World
Xilio shares tumble after mixed vilastobart data - The Pharma Letter
Vilastobart set apart? Xilio phase II combo performs in CRC - BioWorld Online
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Marketscreener.com
Xilio Therapeutics Advances with Phase 2 Trial Data - TipRanks
Xilio Therapeutics Announces Initial Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - Marketscreener.com
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards 60,000-Share Stock Option Grant to New Employee at $0.955 - StockTitan
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Rises By 221.7% - Defense World
Geode Capital Management LLC Grows Position in Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Xilio Therapeutics Inc [XLO] stock for 6,841 USD was sold by Frankenfield Christopher James - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 31.9% in December - Defense World
Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment - Defense World
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com India
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Australia
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewswire
Xilio Therapeutics Hires Caroline Hensley as Chief Legal Officer - Bloomberg Law
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics, Inc. Appoints Caroline Hensley as chief legal officer -December 16, 2024 at 07:30 am EST - Marketscreener.com
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - The Bakersfield Californian
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 317.4% - Defense World
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - MSN
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Yahoo Finance
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 89.4% in November - Defense World
Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World
Xilio to present new cancer treatment data at SITC By Investing.com - Investing.com Australia
Xilio Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Xilio Therapeutics Inc. (XLO) Quarterly 10-Q Report - Quartzy
Xilio to present new cancer treatment data at SITC - Investing.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewswire
Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan
Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xilio Therapeutics Inc Stock (XLO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
| GILEAD SCIENCES, INC. | 10% Owner |
Apr 02 '24 |
Buy |
0.76 |
485,250 |
368,790 |
7,345,473 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 08 '24 |
Sale |
0.64 |
733 |
469 |
2,019,563 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 08 '24 |
Sale |
0.64 |
267 |
171 |
734,546 |
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):